TY  - JOUR
A1  - Bremmer, Felix
A1  - Bohnenberger, Hanibal
A1  - Küffer, Stefan
A1  - Oellerich, Thomas
A1  - Serve, Hubert
A1  - Urlaub, Henning
A1  - Strauß, Arne
A1  - Maatoug, Yasmine
A1  - Behnes, Carl Ludwig
A1  - Oing, Christoph
A1  - Radzun, Heinz-Joachim
A1  - Ströbel, Philipp
A1  - Balabanov, Stefan
A1  - Honecker, Friedemann
T1  - Proteomic comparison of malignant human germ cell tumor cell lines
T2  - Disease markers
N2  - Malignant germ cell tumors (GCT) are the most common malignant tumors in young men between 18 and 40 years. The correct identification of histological subtypes, in difficult cases supported by immunohistochemistry, is essential for therapeutic management. Furthermore, biomarkers may help to understand pathophysiological processes in these tumor types. Two GCT cell lines, TCam-2 with seminoma-like characteristics, and NTERA-2, an embryonal carcinoma-like cell line, were compared by a quantitative proteomic approach using high-resolution mass spectrometry (MS) in combination with stable isotope labelling by amino acid in cell culture (SILAC). We were able to identify 4856 proteins and quantify the expression of 3936. 347 were significantly differentially expressed between the two cell lines. For further validation, CD81, CBX-3, PHF6, and ENSA were analyzed by western blot analysis. The results confirmed the MS results. Immunohistochemical analysis on 59 formalin-fixed and paraffin-embedded (FFPE) normal and GCT tissue samples (normal testis, GCNIS, seminomas, and embryonal carcinomas) of these proteins demonstrated the ability to distinguish different GCT subtypes, especially seminomas and embryonal carcinomas. In addition, siRNA-mediated knockdown of these proteins resulted in an antiproliferative effect in TCam-2, NTERA-2, and an additional embryonal carcinoma-like cell line, NCCIT. In summary, this study represents a proteomic resource for the discrimination of malignant germ cell tumor subtypes and the observed antiproliferative effect after knockdown of selected proteins paves the way for the identification of new potential drug targets.
Y1  - 2019
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/51695
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-516957
SN  - 1875-8630
SN  - 0278-0240
N1  - Copyright © 2019 Felix Bremmer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The publication of this article was funded by Max Planck.
VL  - 2019
IS  - Art. 8298524
SP  - 1
EP  - 14
PB  - Hindawi
CY  - New York, NY [u. a.]
ER  -